register

News - Biotechnology

‘We still hold deep concerns’: 18 organisations challenge Chalmers’ R&D tax reforms

Health Industry Hub | October 8, 2026 |

Eighteen of Australia’s leading life sciences, research, science and deep-tech organisations* have warned Treasurer Jim Chalmers that proposed changes to the R&D Tax Incentive (RDTI) and Innovative Business CGT Concession (IBCC) will perversely push innovation offshore.

The warning comes after the Albanese Government revised several elements of its proposed startup and innovation tax settings following industry backlash, but as Treasury moves to finalise the reforms, deep concerns remain.

The organisations argue the proposed settings fail to reflect the unusually long and capital-intensive development cycles of biotech, medtech, health tech and deep-tech companies, particularly those progressing through clinical trials. They are calling for the proposed age limits on both concessions to be scrapped, or extended to at least 20 years, while demanding that companies actively undertaking clinical trials face no age limit for the refundable RDTI.

The warning is particularly pointed given the government’s stated ambition to build sovereign capability in critical technologies and life sciences.

“Company age remains a poor proxy for commercial maturity, growth potential or R&D intensity in science-based and deep tech sectors,” the letter to Chalmers warns. “As currently drafted the proposed time limit to the refundable RDTI risks encouraging early-stage research in Australia, but then pushing later-stage development including clinical trials and manufacturing activities offshore, and causing significant unintended consequences to Australia’s world-renowned clinical trials industry and broader innovation ecosystem.”

The problem is particularly acute for companies that remain pre-revenue well into their second decade and may only then be entering their most R&D-intensive phase.

The groups are also taking aim at the proposed removal of RDTI eligibility for so-called supporting activities, warning that the change could materially undermine the economics of Australian life sciences R&D.

An analysis of Australian life sciences companies indicates that removing supporting R&D activities from RDTI eligibility from FY2029 could reduce the refundable R&D tax offset received by participating companies by up to 60%, despite no change to the underlying science, risk, or legally required development activities.

“In particular, R&D for the purposes of developing a therapeutic good cannot progress without extensive ‘supporting’ regulatory, manufacturing and analytical activities,” the letter states. “Indeed, these ‘supporting’ activities are inextricably linked to, and legally required for the conduct of core research and clinical trials.”

The organisations are also pressing for innovative publicly listed companies to qualify for the IBCC, arguing that excluding them could distort capital allocation and make offshore funding comparatively more attractive. For companies whose development programs demand repeated injections of capital, they argue, an IPO is not an exit from innovation but a potential source of funding for the next stage of research, clinical trials, manufacturing scale-up and commercialisation.

Taken together, the reforms risk undermining Australia’s ability to keep high-value R&D onshore at precisely the point when global competition for capital, technology and talent is intensifying.

*The letter was signed by AusBiotech, ANDHealth, Association of Australian Medical Research Institutes, AUScelerate, Australian Academy of Science, Australian Academy of Technological Sciences and Engineering, BioMelbourne Network, BioNSW, Cicada Innovations, Jumar Bioincubator, Life Sciences Australia, Life Sciences Queensland, Life Sciences WA, Medical Technology Association of Australia, Medicines Australia, Pathology Technology Australia, Research Australia and Science & Technology Australia.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News - MedTech & Diagnostics

Roche unlocks new horizons for genomic research in Asia Pacific

Roche unlocks new horizons for genomic research in Asia Pacific

Health Industry Hub | November 9, 2026 |

Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]

More


News - Pharmaceuticals

'Unexpected and Surprising': Novartis’ Lp(a) setback raises tough questions for Amgen and Lilly - Professor Stephen Nicholls, Victorian Heart Hospital

‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly

Health Industry Hub | November 9, 2026 |

The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]

More


News - MedTech & Diagnostics

More public hospitals turn to same-day hip and knee surgery but recovery risks persist

More public hospitals turn to same-day hip and knee surgery, but key blind spots persist

Health Industry Hub | November 9, 2026 |

Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]

More


News - Pharmaceuticals

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

Health Industry Hub | November 9, 2026 |

The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]

More


This content is copyright protected. Please subscribe to gain access.